Madrigal Pharmaceuticals, Inc. Common Stock MDGL

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.

• The Motley Fool 16 jun

  3 Under-the-Radar Stocks to Buy and Hold for a Decade

  The article highlights three biotech companies with strong growth potential over the next decade: Madrigal Pharmaceuticals, which has the first-approved MASH treatment with significant market opportunity; Axsome Therapeutics, which is expanding its depression medicine Auvelity into Alzheimer's disease treatment; and Kailera Therapeutics, a newly public company developing weight-loss medicines in a fast-growing market. All three operate in high-need therapeutic areas with promising pipelines.

  

• GlobeNewswire Inc. 11 feb

  Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs

  Madrigal Pharmaceuticals announced an exclusive global licensing agreement with Suzhou Ribo Life Science for six preclinical siRNA programs to expand its MASH treatment pipeline. The deal includes a $60 million upfront payment with potential cumulative payments reaching $4.4 billion upon milestone achievement. Madrigal's pipeline now includes over 10 programs anchored by its approved drug Rezdiffra, with additional candidates including MGL-2086 (GLP-1 agonist) and Ervogastat (DGAT-2 inhibitor) in development.

  

• GlobeNewswire Inc. 17 nov

  Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

  Madrigal Pharmaceuticals will participate in three upcoming healthcare investor conferences in November and December 2025, presenting live webcasts about their MASH treatment Rezdiffra.

  

• GlobeNewswire Inc. 10 nov

  Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis

  Madrigal Pharmaceuticals presented two-year data on Rezdiffra, demonstrating significant improvements in liver imaging tests and biomarkers for patients with compensated MASH cirrhosis, highlighting potential benefits across different patient populations.

  

• The Motley Fool 5 ago

  Madrigal (MDGL) Q2 Revenue Soars 1,313%

  Madrigal Pharmaceuticals reported strong Q2 2025 performance, with GAAP revenue of $212.8 million for its MASH therapy Rezdiffra, exceeding estimates by 31.3%. The company saw rapid patient adoption, with over 23,000 patients on the drug and expanding commercial operations.